ArticleJournal of medicinal chemistry2019
De Novo Designed Amphipathic α-Helical Antimicrobial Peptides Incorporating Dab and Dap Residues on the Polar Face To Treat the Gram-Negative Pathogen, Acinetobacter baumannii.
Article in Journal of medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Evolution-driven terminal capping design in antimicrobial peptides revealed by combined experimental and MD simulation approaches.Archives of microbiology · 2026Article
- The antimicrobial peptide EM86 loaded to gamma-irradiated sodium alginate/polyvinyl alcohol electrospun nanofibrous dressing treated multidrug-resistantFrontiers in bioengineering and biotechnology · 2026Article
- Antimicrobial Peptides in Focus: Functional Potential and Translational Evidence from Swine Systems.ACS omega · 2025Review
- Influence of hydrophobicity on the antimicrobial activity of helical antimicrobial peptides: a study focusing on three mastoparans.Molecular diversity · 2025Article
- Unlocking the power of antimicrobial peptides: advances in production, optimization, and therapeutics.Frontiers in cellular and infection microbiology · 2025Review
- Branched tetrameric lactoferricin peptides modified with diaminopropionic acid exhibit potent antimicrobial and wound-healing activities.Frontiers in pharmacology · 2025Article
- Dual Antimicrobial and Anticancer Activity of Membrane-Active Peptide BP52.The protein journal · 2024Article
- Reducing Self-Assembly by Increasing Net Charge: Effect on Biological Activity of Mastoparan C.ACS medicinal chemistry letters · 2024Article
- Dimerization and lysine substitution of melittin have differing effects on bacteria.Frontiers in pharmacology · 2024Article
- Article
- An Update on the Therapeutic Potential of Antimicrobial Peptides againstPharmaceuticals (Basel, Switzerland) · 2023Review
- Article
- A novel series of dipeptide derivatives containing indole-3-carboxylic acid conjugates as potential antimicrobial agents: the design, solid phase peptide synthesis,RSC advances · 2023Article
- Effect of substituting glutamine with lysine on structural and biological properties of antimicrobial peptide Polybia-MP1.Amino acids · 2023Article
- Structure-Based Rational Design of Small α-Helical Peptides with Broad-Spectrum Activity against Multidrug-Resistant Pathogens.Journal of medicinal chemistry · 2023Article
- Antimicrobial and Cell-Penetrating Peptides: Understanding Penetration for the Design of Novel Conjugate Antibiotics.Antibiotics (Basel, Switzerland) · 2022Review
- A Novel Antimicrobial Peptide SpampcinInternational journal of molecular sciences · 2022Article
- Rescuing humanity by antimicrobial peptides against colistin-resistant bacteria.Applied microbiology and biotechnology · 2022Review
- Article
- Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
We have designed de novo and synthesized ten 26-residue D-conformation amphipathic α-helical cationic antimicrobial peptides (AMPs), seven with "specificity determinants", which provide specificity for prokaryotic cells over eukaryotic cells. The ten AMPs contain five or six positively charged residues (d-Arg, d-Lys, d-Orn, l-Dab, or l-Dap) on the polar face to understand their role in hemolytic activity against human red blood cells and antimicrobial activity against seven Acinetobacter baumannii strains, resistant to polymyxin B and colistin, and 20 A. baumannii worldwide isolates from 2016 and 2017 with antibiotic resistance to 18 different antibiotics. AMPs with specificity determinants and with l-Dab and l-Dap residues on the polar face have essentially no hemolytic activity at 1000 μg/mL (380 μM), showing for the first time the importance of these unusual amino acid residues in solving long-standing hemolysis issues of AMPs. Specificity determinants maintained excellent antimicrobial activity in the presence of human sera.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.